Aims To investigate the kinetics of the (+)RS-and (−)SR-enantiomers and the carboxylic acid metabolite (MMQ) of the antimalarial drug mefloquine (MQ) in healthy volunteers. Methods Ten subjects of which three were poor metabolizers of debrisoquine received racemic MQ 250 mg once weekly for 16 weeks. The kinetics were followed in plasma and urine and evaluated by individual kinetic modelling as well as by a nonparametric population kinetic method. Results A two-compartment model adequately described the disposition of (+)RS-MQ. CL/F was 6.5±1.8 l h The aims of the present study were to investigate the treatment of multi-drug resistant P. falciparum malaria. The available preparation is a racemate of the (+)RS-MQ and enantioselective kinetics of MQ during long-term prophylaxis including the early phase after drug intake, the renal (−)SR-MQ enantiomers. Both enantiomers are active against P. falciparum in vitro [1] although a slightly higher excretion of the enantiomers and to define any difference between poor and extensive metabolizers of debrisoquine in activity for (+)RS-MQ has been reported [2] . A major problem with MQ is the occurrence of neuropsychiatric the elimination of the MQ enantiomers. For determination of the typical kinetic characteristics for (+)RS-MQ and adverse reactions, in particular after therapeutic doses [3]. It has not been clarified whether the potential to cause adverse (−)SR-MQ in this population, we performed a population analysis using the nonparametric NPEM method [8]. reactions differs between the enantiomers. MQ is a local irritant that cannot be given intravenously. Hence, absolute
Introduction difference in AUC at steady-state was 6.6-fold. Similar findings have been reported in Thai volunteers given a Mefloquine (MQ), a quinoline methanol chemically related to quinine, is an important drug for malaria prophylaxis and single dose of 750 mg MQ [7] . The aims of the present study were to investigate the treatment of multi-drug resistant P. falciparum malaria. The available preparation is a racemate of the (+)RS-MQ and enantioselective kinetics of MQ during long-term prophylaxis including the early phase after drug intake, the renal (−)SR-MQ enantiomers. Both enantiomers are active against P. falciparum in vitro [1] although a slightly higher excretion of the enantiomers and to define any difference between poor and extensive metabolizers of debrisoquine in activity for (+)RS-MQ has been reported [2] . A major problem with MQ is the occurrence of neuropsychiatric the elimination of the MQ enantiomers. For determination of the typical kinetic characteristics for (+)RS-MQ and adverse reactions, in particular after therapeutic doses [3] . It has not been clarified whether the potential to cause adverse (−)SR-MQ in this population, we performed a population analysis using the nonparametric NPEM method [8] . reactions differs between the enantiomers. MQ is a local irritant that cannot be given intravenously. Hence, absolute
Compared with the standard two-stage method, more accurate estimates of the distribution of kinetic parameters bioavailability and systemic clearance are not known. The metabolism of MQ is not well characterised. At steady-state, in a population can be obtained with the population methodology as it takes into account the quality of the data an average of 9% of the dose is excreted unchanged in urine and 4% as the carboxylic acid metabolite (MMQ) [4] . MMQ from each subject and the covariance between the parameters. is regarded as the main metabolite in man but it has no significant antimalarial effect in vitro [5] . Methods A recent pharmacokinetic study during prophylactic intake of MQ (250 mg once weekly) demonstrated a Subjects significantly longer mean half-life of (−)SR-MQ compared Ten healthy adult Caucasian volunteers (mean age 42 years, range 29-50 years, six females and four males) participated hydroxylators of debrisoquine according to a previous according to the inverse of the concentration. The kinetic parameter k for MMQ was determined from data after the phenotyping. Before inclusion, a health check-up including medical history, physical examination and blood chemistry last drug intake. In the population kinetic analyses, all data for each was carried out. One subject (1) was on continuous antihistamine treatment (loratadine) and one subject (2) was enantiomer were pooled and evaluated separately with the NPEM-method. An error model was first defined based on on anticonceptive therapy (Depot-Provera injection every 3 months). The study was approved by the local ethics the standard deviation of the analytical method at different concentrations. We tested both one-and two-compartment committee at Huddinge University Hospital (11/92).
pharmacokinetic models and compared the outcomes. The renal excretion of unchanged (+)RS-MQ and (−)SR-MQ as a fraction of the administered dose was Study design calculated from the total amount excreted during one dose Racemic mefloquine (LariamA, Hoffman La Roche, interval at steady-state. Switzerland) was given in the adult prophylactic dose of 250 mg once weekly for a total of 16 weeks. The aim was
Statistical methods to reach steady-state conditions in all subjects. All volunteers took the first and last MQ dose on an empty stomach Parametric correlation analyses were carried out for the (fasting for at least 10 h) and remained fasting during the clearance of (+)RS-MQ vs the clearance of (−)SR-MQ, first 3 h after intake. Food was allowed with the other doses.
as well as for the volume of distribution of (+)RS-MQ vs The subjects filled out a standardized questionnaire about (−)SR-MQ. The 95% confidence interval (CI) for the typical adverse effects of mefloquine once weekly during difference between groups or occasions was calculated when the study. They also participated in a separate study of appropriate. For the (+)RS-MQ enantiomer, a two-compartment model used. Samples were centrifuged within 30 min and plasma was superior in 9/10 cases when compared with a onewas frozen for later drug analysis. compartment model. The mean value for AIC in all subjects Urine was collected in 24 h intervals during 7 days after was −97.2 with a one-compartment model, and −111.9 intake of the last dose.
with a two-compartment model. Individual parameter values are presented in Table 1 . The kinetics were stable over time with a similar quality of the fits after the first and after the Analytical methods last dose. The kinetic behaviour of the (−)SR-MQ enantiomer Plasma and urine levels of (+)RS-MQ and (−)SR-MQ was highly erratic with a higher mean relative peak MQ and MMQ (2,8-bis(trifluoromethyl)-4-quinoline carconcentration and a longer half-life after the last dose boxylic acid) were determined by h.p.l.c. [10, 11] . The compared with the first dose ( Table 1) . We also found limits of determination related to the free base were 0.25 mm fluctuations in the concentrations of (−)SR-MQ during [95 mg l ] for (−)SR-MQ. For the enantias shown in Figure 1 . We were unable to include all of omers, the intra-and inter-assay coefficients of variation these phenomena in a general model and therefore used a were below 10% within the range of close to all concenconventional approach with a one-compartment model trations measured in this study. A number of measured which most adequately described the data. According to concentrations for (+)RS-MQ were at the above stated AIC, a one-compartment model was superior in 7/10 cases limit of determination at which the intra-and inter-assay (mean value for AIC was 30.97 for a one-compartment coefficients of variation were between 10% and 17%. model and 31.72 for a two-compartment model). Due to the change in kinetics over time for (−)SR-MQ, three evaluations were conducted with different data sets: one Pharmacokinetic methods with all data in one sequence, one with the data after the first dose only (up to the administration of the second dose), Separate analyses were carried out for the two enantiomers and the MMQ metabolite. The software PCNONLIN was and one with the data after the last dose only. The halflife for the terminal elimination of (−)SR-MQ after the used for individual modelling of the concentration over time. The parameter values were evaluated using the kinetic last dose was accurately estimated despite using a onecompartment model, as the concentration was determined model that gave the best fit to the data according to Akaike's information criterion, AIC [12] . All data for each subject on several occasions up to 6 weeks post dose intake. The results of all three evaluations are shown in Table 1 . were evaluated in one sequence. Data were weighted Within subject comparisons showed that the oral clearances of (−)SR-MQ and (+)RS-MQ were significantly correlated (r=0.69, P<0.05). The same was found for V/F (r=0.66, P<0.05). CL/F and V/F were not correlated for any of the enantiomers.
The concentration of MMQ increased continuously during the first 8 weeks with minor fluctuations during the dose interval. The values of k (Table 1) were lower than the corresponding values for both (+)RS-MQ and rate-limited and not determined by its rate of formation. during 7 days after the last dose intake at week 16.
Observed trough values during week 15 were in all cases higher than the corresponding values for (+)RS-MQ and (−)SR-MQ. Poor metabolizers of debrisoquine did not The analyses show that the kinetics of the two enantiomers differ considerably. The maximal observed concentration differ from extensive metabolizers in any of the kinetic parameters for (+)RS-MQ, (−)SR-MQ or the MMQ (C max ) after the first dose was higher for (−)SR-MQ than for (+)RS-MQ (0.65±0.16 vs 0.30±0.06 mm, 95% CI metabolite, according to the Mann-Whitney U test. However, the statistical power of this comparison is low for the difference 0.28-0.43 mm). The mean clearance of (+)RS-MQ at steady-state was on average six times higher due to the limited number of subjects in the study. Oral clearance of (+)RS-MQ was 5.6±1.86 l h −1 in PMs and than that of (−)SR-MQ (5.7±1.7 vs 0.94±0.26 l h Clearance of (−)SR-MQ decreased more than twofold in EMs CL/F 0.93±0.21 l h −1 and V/F 577±114 l.
of the (−)SR-MQ concentration during the first days after Population kinetic evaluation intake was a common observation. Both enterohepatic recirculation and extended irregular absorption may contrib-A two-compartment model was superior to describe (+)RS-MQ kinetics as shown by the value of the ute to this. From observations in the rat, it has been proposed that MQ undergoes enterohepatic circulation as log-likelihood compared with a one-compartment model (−2332 vs −2618). This was true also for (−)SR-MQ well as metabolism in the gastrointestinal wall [13] . The high within subject correlation of both CL/F and V/F with a minor difference in the log-likelihood (−2791 vs −2872). We chose a one-compartment model for between (+)RS-MQ and (−)SR-MQ suggests that the enantiomers to some extent use similar enzymatic pathways (−)SR-MQ due to the difficulties to describe adequately the concentration-time curve for (−)SR-MQ with a twoin their metabolism. If this is true, however, the affinity of the most important isozymes must be higher since compartment model. Values of the population kinetic parameters are included in Table 1 . Figure 2 shows simulated (+)RS-MQ is cleared much more efficiently. Approximately 10% of the total administered rac MQ was concentration curves for each enantiomer based on the population kinetic parameters found in this study, together excreted unchanged in urine with a slightly higher value for (−)SR-MQ than for (+)RS-MQ. If the bioavailability of with individual concentration curves.
the MQ enantiomers is less than 100%, renal clearance will account for a larger fraction of the total clearance than the Renal excretion approximately 10% estimated in this study. This implies that renal function may be an important factor when dosing MQ The amount excreted unchanged during one dose interval at steady-state (week 15) was 28.8±6.6 (range 15. 4-36.4) for long periods. A reduction in the clearance of the enantiomers will result in a prolonged half-life. Due to the mmol of (+)RS-MQ and 40.6±12.3 (range 24.2-63.2) mmol of (−)SR-MQ. The 95% CI for the difference was very long half-life of MQ in subjects with normal renal function, an extended dosing period is required to detect 4.5-19.2 mmol. Expressed as a fraction of the administered dose, the mean amount of (+)RS-MQ was 8.7% and of the effects of a moderate reduction in clearance. The kinetics of MQ have been studied in two haemodialysis patients (−)SR-MQ 12.3%. There was a trend to correlation between the renal excretion of the enantiomers (r=0.55, receiving the malaria prophylaxis dose [14] . One patient had similar concentrations of MQ after the dose intake at P<0.1). The true renal clearance could not be calculated due to the very long half-life of both enantiomers, making week 6 and at week 7, suggesting that steady-state was attained within 7 weeks of repeated intake. It was not a regression of plasma AUC against amount excreted in urine very uncertain.
proven for the second patient that steady-state had been attained. The MQ concentrations 28 days after the last dose intake were for both patients within the same range as Discussion observed in healthy volunteers with a similar dose regimen. We do not consider these data as a proof that renal function In a previous study where stereoselective kinetics of MQ enantiomers were shown, the sampling schedule did not has no importance for MQ kinetics. Only one patient was suggested to have attained steady-state from only two allow compartmental modelling or characterisation of the early phase after drug intake [6] . New findings in the present repeated concentration measurements. A larger sample of subjects with impaired renal function on MQ prophylaxis is study are the time-dependent kinetics of (−)SR-MQ, the possible enterohepatic recirculation of (−)SR-MQ, the required to study the relationship between MQ kinetics and renal function. within subject correlation of both V/F and CL/F for the enantiomers and the likely lack of influence of the CYP2D6
The current recommendation for prophylaxis to take 250 mg once weekly and to start this regimen 1 week before phenotype on the kinetics of (+)RS-MQ, (−)SR-MQ and MMQ. It is obvious that modelling of racemic MQ is entering an area with malaria (i.e. not before the intake of the second dose), results in a total concentration of MQ inadequate as the enantiomers differ not only in kinetic parameters but also in other aspects of their disposition.
during the second week that is about half of the concentration at steady-state. A longer loading phase or a shorter initial The (+)RS-MQ-enantiomer fitted well into a twocompartment model. We obtained similar results with the dosing interval would result in concentrations closer to steady-state at the first time of possible exposure to malaria. two-stage method based on individual results and the population approach (Table 1) .
Compared with (−)SR-MQ, (+)RS-MQ has many kinetic advantages. In this study, the half-life was shorter The (−)SR-MQ-enantiomer showed an unexpected kinetic behaviour. The more than double mean peak with a more rapid achievement of steady-state, kinetics were not time-or concentration dependent, and no signs of concentration after the first dose compared with (+)RS-MQ indicates that the bioavailability of (+)RS-MQ may be low. enterohepatic recycling were found. However, it cannot be excluded that such phenomena would occur if (+)RS-MQ The bioavailability of MQ is unknown as an intravenous formulation of rac MQ is unavailable. We have no clear alone was given in high enough doses to achieve a prophylactic or therapeutic effect. In addition, the adverse explanation for the higher relative peak concentration of (−)SR-MQ after the last dose compared with the first dose.
effect profile of this enantiomer at high concentrations needs to be studied. A capacity limited first-pass metabolism becoming saturated at higher systemic concentrations is one possibility, which would be in agreement with the observed longer terminal 
